Erasca (ERAS) Free Cash Flow (2020 - 2026)
Erasca (ERAS) reported Free Cash Flow of -$27.4 million for Q1 2026, up 13.34% on a YoY basis from -$24.2 million in Q1 2025, and down 26.24% quarter-over-quarter from -$21.7 million in Q4 2025.
Erasca (ERAS) Free Cash Flow (2020 - 2026) Analysis & Trends
Erasca has reported Free Cash Flow for 7 years, with the latest figure at -$27.4 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 13.34% year-over-year to -$27.4 million; the trailing twelve-month figure through Mar 2026 stood at -$91.4 million (up 15.26% YoY), and the FY2025 full-year result was -$95.6 million, up 12.69% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$27.4 million, down from -$21.7 million in the prior quarter.
- The five-year high for Free Cash Flow was -$20.6 million in Q2 2025, with the low at -$33.3 million in Q1 2024.
- Historically, Free Cash Flow has averaged -$26.7 million across 5 years, with a median of -$26.2 million in 2023.
- Annual changes were most pronounced in 2022 — Free Cash Flow plunged 109.92% — and 2025, when it climbed 29.58%.
- Erasca's Free Cash Flow stood at -$27.2 million in 2022, then advanced by 8.69% to -$24.9 million in 2023, then climbed by 1.23% to -$24.6 million in 2024, then advanced by 11.58% to -$21.7 million in 2025, then fell by 26.24% to -$27.4 million in 2026.
- The last three Free Cash Flow figures came in at -$27.4 million (Q1 2026), -$21.7 million (Q4 2025), and -$21.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - | -27.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.42 Mn |
| Mar 31, 2026 | -27.42 Mn |
| Dec 31, 2025 | -21.72 Mn |
| Dec 31, 2025 | -21.72 Mn |
| Sep 30, 2025 | -21.66 Mn |
| Sep 30, 2025 | -21.66 Mn |
| Jun 30, 2025 | -20.56 Mn |
| Jun 30, 2025 | -20.56 Mn |
| Mar 31, 2025 | -31.64 Mn |
| Mar 31, 2025 | -31.64 Mn |
| Dec 31, 2024 | -24.56 Mn |
| Dec 31, 2024 | -24.56 Mn |
| Sep 30, 2024 | -22.42 Mn |
| Sep 30, 2024 | -22.42 Mn |
| Jun 30, 2024 | -29.20 Mn |
| Jun 30, 2024 | -29.20 Mn |
| Mar 31, 2024 | -33.29 Mn |
| Mar 31, 2024 | -33.29 Mn |
| Dec 31, 2023 | -24.87 Mn |
| Dec 31, 2023 | -24.87 Mn |